Clinical Pharmacogenetics Implementation Consortium
What is CPIC?
The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.
One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.
CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications). CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.
CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.
Additionally, the College of American Pathologists (CAP) has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”
CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.
Team
CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital
Teri E. Klein, Ph.D.
Stanford University
Co-Investigator
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University
James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital
Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University
Steering Committee
Teri E. Klein, Ph.D.
Stanford University
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital
Michelle Whirl-Carrillo, Ph.D.
Stanford University
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital
Dan M. Roden, M.D.
Vanderbilt University
Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH
Larisa Cavallari, Pharm.D.
University of Florida
Stuart A. Scott, Ph.D.
Stanford University and Stanford Healthcare
Sara Van Driest, M.D., Ph.D.
Vanderbilt University
Scientific Advisory Board
Julie A. Johnson, Pharm.D.
University of Florida
Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories
Robert Nussbaum, M.D.
University of California, San Francisco
Heidi Rehm, Ph.D.
Partners Healthcare
Marc S. Williams, M.D.
Geisinger
Sandy Aronson
Partners Personalized Medicine
Justin B. Starren, M.D., Ph.D.
Northwestern University
Houda Hachad, Pharm.D., M. Res.
AccessDx/Medtek21
Andrea Gaedigk, Ph.D.
Children’s Mercy
News & Announcements
- ClinGen is hosting a Clinical Genomics Career Panel webinar series this summer for individuals interested in career in clinical genomics. Sessions are moderated and panel members will discuss their work and career paths. All are welcome to join!
- The PharmGKB Acyclovir/Ganciclovir Pathway has recently been published in the journal Pharmacogenetics and Genomics.Acyclovir (ACV) and ganciclovir (GCV) are commonly prescribed antivirals to treat infections caused by herpes viruses, varicella-zoster virus or cytomegalovirus (eg. cold sores, shingles and chicken pox, etc.). The pathway, co-developed by Maud Maillard along with other members of the Yang Lab in St. Jude, as well […]
- Oregon Health & Science University (OHSU) will introduce new educational initiatives on the risks of prescribing the chemotherapy drug capecitabine to patients with DPD deficiency as part of a lawsuit settlement.The settlement was reached with Joanne McIntyre, whose husband David died as a result of severe capecitabine toxicity. David carried variations in the gene DPYD, which […]
- The latest round of PharmGKB’s pediatric drug summaries is now live on PharmGKB pediatric. This release includes summaries for 55 drugs, bringing the total summary count to over 180, now including all drugs on the Best Pharmaceuticals for Children Act (BPCA) priority list in addition to all CPIC guideline drugs.Drugs with new summaries include:AlfentanilAmiodaroneAmpicillinAzithromycinBosentanCidofovirCiprofloxacinClindamycinClonidineDexmedetomidineDigoxinDoxycyclineFurosemideGranisetronGriseofulvinHeparinHydralazineHydrochlorothiazideHydromorphoneHydroxycobalaminHydroxyureaIsotretinoinLabetalolLevofloxacinLevothyroxineLidocaineLisinoprilLithiumLorazepamLurasidoneMeropenemMetforminMethylprednisoloneMidazolamMolindoneNafcillinNicardipineNifedipineNifurtimoxOlanzapinePentobarbitalPiperacillin-TazobactamPralidoximePrednisoloneSertralineSildenafilSpironolactoneTerbutalineTimololTopiramateTranexamic AcidValganciclovirVancomycinVecuronium
- On May 2nd, the American Academy of Pediatrics (AAP) released a pre-published policy statement titled “Eliminating Race-Based Medicine,” noting that race is a “historically derived social construct that has no place as a biologic proxy.” The statement provides necessary and meaningful commentary on “the medical field’s history of inaccurate applications of race correction and adjustment […]